Peel Hunt reaffirmed their hold rating on shares of Victrex (LON:VCT) in a research note released on Thursday morning, Stock Target Advisor reports.
Several other research firms have also commented on VCT. Liberum Capital restated a buy rating on shares of Victrex in a research note on Thursday. UBS Group reaffirmed a neutral rating on shares of Victrex in a report on Monday, November 25th. Stifel Nicolaus downgraded Victrex to a hold rating and lowered their target price for the company from GBX 2,255 ($29.47) to GBX 2,125 ($27.77) in a research report on Friday, September 27th. Credit Suisse Group reissued an outperform rating on shares of Victrex in a report on Tuesday, November 12th. Finally, Barclays reduced their price target on Victrex from GBX 2,020 ($26.39) to GBX 1,940 ($25.35) and set an equal weight rating for the company in a research report on Wednesday, November 27th. Eight research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of GBX 2,261.50 ($29.55).
Shares of Victrex stock traded up GBX 46 ($0.60) on Thursday, hitting GBX 2,372 ($30.99). 322,161 shares of the company’s stock were exchanged, compared to its average volume of 274,177. The company has a 50-day simple moving average of GBX 2,300.24 and a 200-day simple moving average of GBX 2,113.34. The stock has a market capitalization of $2.05 billion and a PE ratio of 20.63. Victrex has a 1 year low of GBX 1,813.68 ($23.70) and a 1 year high of GBX 2,544 ($33.24).
Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, ortho, dental, trauma, knee, cardiovascular, and orthopedic applications. It also offers specialist solutions for medical device manufacturers.
Further Reading: What are benefits of a growth and income fund?
Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.